Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Radboud University |
---|---|
Information provided by: | Radboud University |
ClinicalTrials.gov Identifier: | NCT00306319 |
Pharmacokinetic study in TB patients to determine the effect of rifampicin on the pharmacokinetic profile of moxifloxacin.
Condition | Intervention | Phase |
---|---|---|
Tuberculosis |
Drug: moxifloxacin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | Pharmacokinetic Interaction Study of Rifampicin, Isoniazid and Moxifloxacin in Tuberculosis Patients in Bandung, Indonesia |
Estimated Enrollment: | 23 |
Study Start Date: | January 2006 |
Study Completion Date: | May 2006 |
Primary Completion Date: | May 2006 (Final data collection date for primary outcome measure) |
Tuberculosis is an infectious disease that still causes many victims in the developing world, especially in Indonesia. Rifampicin, isoniazid and ethambutol are the cornerstone of the current treatment. The disadvantage of the current treatment is the long, six-months, duration of the treatment. This long duration contributes to suboptimal adherence to the TB drugs.Thus, there is a very urgent need to evaluate drugs that may help shortening TB treatment. The fluoroquinolone moxifloxacin has shown early bactericidal activity (EBA) in patients with pulmonary TB, and has shown rapid and reliable sterilization. Rifampicin is a strong inducer of the CYP enzymes, but it also induces phase II metabolism. As moxifloxacin is metabolized by phase II metabolism, rifampicin could cause a decrease in the plasma concentrations of moxifloxacin. Therefore, a pharmacokinetic interaction study is warranted.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | UMCN-AKF 05.02, Primo study |
Study First Received: | March 22, 2006 |
Last Updated: | May 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00306319 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Tuberculosis |
Bacterial Infections Rifampin Gram-Positive Bacterial Infections Moxifloxacin |
Mycobacterium Infections Tuberculosis Isoniazid |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Actinomycetales Infections |